-
December 10, 2025
LAS VEGAS — A man failed to allege in his complaint against the manufacturer of an implantable medical device for the heart how the device or the company deviated from requirements set by the U.S. Food and Drug Administration, a Nevada federal judge said in finding that the claims are preempted by federal law.
-
December 10, 2025
FORT LAUDERDALE, Fla. — A Florida state judge declared a mistrial after jurors indicated that they could not reach a unanimous verdict after deliberating for weeks in a case brought by Florida hospitals accusing pharmacies of contributing to the opioid crisis through their company policies.
-
December 10, 2025
CAMDEN, N.J. — A manufacturer of losartan products has agreed to pay $1,899,000 to settle claims brought against it by consumers and third-party payers (TPPs) who allege in a multidistrict litigation in a New Jersey federal court that the blood pressure medication was contaminated, according to a motion for preliminary approval of the settlement agreement.
-
December 09, 2025
WHEELING, W.Va. — A West Virginia federal judge on Dec. 9 scheduled a hearing to consider two motions filed by a pharmacy benefits manager (PBM) facing allegations that its actions contributed to an “oversupply” of prescription opioids throughout West Virginia, asking the court to reconsider and issue an emergency stay of the court’s order that compelled the PBM to release nationwide prescription and remuneration data.
-
December 08, 2025
LOS ANGELES — A second amended complaint filed by a woman who alleges that a defective medical device failed during surgery “added allegations to sufficiently rectify” deficiencies identified by a California federal judge in his previous ruling dismissing the complaint, he said in denying manufacturers’ motion to dismiss.
-
December 08, 2025
TAMPA, Fla. — A federal magistrate judge recommended that a Florida federal court grant Eli Lilly & Co.’s motion for a default final judgment after finding that a cosmetic weight loss center likely infringed on trademarks held by the company while selling a compounded version of tirzepatide.
-
December 04, 2025
CHICAGO — Arguments from Eli Lilly & Co. that the U.S. Supreme Court is likely to decide whether the Seventh Circuit U.S. Court of Appeals erred in affirming a final judgment of $193 million for reporting falsely deflated drug prices to the government were unpersuasive, the Seventh Circuit said in denying Lilly’s motion to stay the court’s mandate.
-
December 04, 2025
PENSACOLA, Fla. — The Florida federal judge overseeing the Depo-Provera multidistrict litigation, a group of cases alleging that a long-lasting injectable contraceptive caused women to develop intracranial meningiomas, a type of brain tumor, amended the discovery and briefing order for the five pilot cases, ordering the plaintiffs to disclose their general causation experts by Jan. 1.
-
December 04, 2025
Bristol Myers Squibb Co. (BMS) and Sanofi-Aventis US LLC responded to a complaint filed by Texas alleging that the pharmaceutical companies violated state law by falsely marketing the antiplatelet drug Plavix as effective without disclosing a genetic contraindication by petitioning another state court for declaratory and injunctive relief.
-
December 04, 2025
ATLANTA — The Georgia federal judge overseeing the Paragard intrauterine device (IUD) multidistrict litigation partially granted CooperSurgical Inc.’s motion for summary judgment, finding that the company had no control over the design of the IUD during the time period that the three bellwether plaintiffs allege that they underwent a procedure to implant the device, but the judge deferred ruling on the failure-to-warn claims until after supplemental briefing on causation is submitted.
-
December 04, 2025
SAN FRANCISCO — A group of drugmakers failed to show that two women who allege that prescription medications caused them to develop breast cancer could not possibly recover damages against a California company, a California federal judge held, granting the women’s motions to remand.
-
December 04, 2025
New developments in the following mass tort drug and device cases are marked in boldface type.
-
December 03, 2025
NEW ORLEANS — The manufacturer of a chemotherapy drug that allegedly caused eye injuries had “newly acquired information” about the risk and could have changed its label under the U.S. Food and Drug Administration’s changes-being-effected (CBE) regulation, the Louisiana federal judge overseeing multidistrict litigation ruled, denying a motion by the drugmaker for summary judgment on preemption grounds.
-
December 03, 2025
WASHINGTON, D.C. — A decision by the Ninth Circuit U.S. Court of Appeals that found no error in the certification of a national third-party payer (TPP) class of entities that paid for the diabetes drug Actos, despite the court recognizing that there is no way to calculate the number of class members that were not harmed, should be reviewed by the U.S. Supreme Court to resolve a circuit split on when a court may certify the class action pursuant to Federal Rule of Civil Procedure 23(b)(3), two drug companies argue in a petition for a writ of certiorari.
-
December 03, 2025
CINCINNATI — An Ohio federal judge granted motions to dismiss two companies named in a third-party complaint filed by the manufacturer of a solution used during fertility-related treatments that couples claim was toxic and destroyed their developing embryos after he found that the court lacks personal jurisdiction.
-
December 02, 2025
WASHINGTON, D.C. — Four additional people who allege that a synthetic cartilage implant device used to treat arthritis in a toe joint was defective joined other plaintiffs in urging the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) to centralize all cases, arguing that the appropriate setting is in Illinois, while the device manufacturer tells the JPMDL that centralization is unnecessary.
-
December 02, 2025
BOSTON — A Massachusetts federal judge has sentenced the former chief executive officer of Massachusetts medical device company Magellan Diagnostics Inc. and two of its executives after they each entered guilty pleas in connection with charges that the company concealed that blood lead testing devices malfunctioned and produced inaccurately low lead levels.
-
December 01, 2025
NEW YORK — A New York magistrate judge recommended that a court partially grant a motion to dismiss filed by a cochlear implant manufacturer after finding that many claims are preempted by federal law.
-
November 26, 2025
SEATTLE — A Washington federal judge agreed to strike a series of affirmative defenses raised by two pharmacy benefits managers (PBMs) that a county in the state allegedly helped create and perpetuate the opioid epidemic.
-
November 24, 2025
CHICAGO — The Seventh Circuit U.S. Court of Appeals on Nov. 21 denied petitions for rehearing filed by both parties in a False Claims Act case in which the Seventh Circuit affirmed a final judgment of $193 million for reporting falsely deflated drug prices to the government.
-
November 21, 2025
AUSTIN, Texas — The Texas Supreme Court on Nov. 21 denied a motion for rehearing filed by a group of pharmacies, letting stand its decision to refuse to review a lower court’s ruling that allowed a case filed against them by Texas counties for their role in the opioid epidemic to proceed, rejecting arguments by the pharmacies that the case will leave those counties “emboldened to find another set of businesses to target” and “could cause serious harm to people across this State.”
-
November 20, 2025
NEW YORK — The judge in the U.S. Bankruptcy Court for the Southern District of New York overseeing the Purdue Pharma LP case has signed off on a $7.4 billion agreement to settle claims that the company and its owners, the Sackler family, contributed to creating the opioid crisis.
-
November 20, 2025
New developments in the following mass tort drug and device cases are marked in boldface type.
-
November 19, 2025
BIRMINGHAM, Ala. — Health care providers unknowingly used a contaminated saline solution to flush a man’s catheter following surgery, causing the man to develop sepsis and die, his widow alleges in a complaint filed in an Alabama federal court against the manufacturer and distributors of the solution.
-
November 19, 2025
LEXINGTON, Ky. — A man’s claims that an implantable medical device for the heart failed and required surgical removal and replacement “face an insurmountable threshold problem: federal preemption,” the device manufacturer argues in a motion to dismiss.